iCellate Medical AB

iCellate Medical AB is a Swedish life-science company established in 2011, specializing in cancer diagnostics and precision oncology services.

Headquartered in Solna/Stockholm, the company originated from research at the Karolinska Institute, collaborating with Karolinska University Hospital and KTH. The company focuses on cancer profiling throughout the cancer lifecycle, including hereditary cancer risk assessment, early detection, treatment selection, and monitoring. Its platform analyzes tumor-derived material from blood samples, such as circulating tumor cells and genomic DNA, to assist clinicians in detecting cancer earlier and making personalized treatment decisions. Key offerings include the CellMate® platform for cancer cell detection, GeneMate® for hereditary cancer testing, liquid biopsy-based diagnostic services, and a companion diagnostic test for Ewing sarcoma. iCellate serves a diverse customer base, including clinicians, healthcare organizations, academic institutions, and pharmaceutical companies, primarily in Europe and North America. Its solutions are utilized in both research and clinical settings to advance personalized medicine and cancer studies.